Curated News
By: NewsRamp Editorial Staff
January 29, 2026
Soligenix Advances Novel Light Therapy for Hard-to-Diagnose Skin Cancer
TLDR
- Soligenix's HyBryte therapy offers a competitive edge by providing a safer, targeted treatment for early-stage CTCL with proven efficacy, potentially capturing a niche market.
- HyBryte works as a visible light-activated photodynamic therapy that selectively targets malignant T-cells in the skin while minimizing damage to surrounding healthy tissue.
- This therapy improves patient outcomes by offering a safer, effective treatment for a difficult-to-diagnose cancer, enhancing quality of life for those with rare diseases.
- HyBryte uses synthetic hypericin activated by red-yellow light, a novel approach that avoids the long-term risks of traditional ultraviolet phototherapies for CTCL.
Impact - Why it Matters
This development matters because CTCL is notoriously difficult to diagnose early, often leading to delayed treatment and poorer outcomes. HyBryte's visible light-activated approach offers a safer alternative to traditional phototherapies, reducing long-term risks like skin damage and cancer. For patients, this means a more targeted treatment with fewer side effects, potentially improving quality of life. In the broader healthcare landscape, it addresses an unmet need in rare diseases, showcasing innovation in biopharmaceuticals. Success here could also accelerate Soligenix's other therapies, benefiting conditions like psoriasis and inflammatory diseases, while highlighting the role of specialized platforms like InvestorWire in communicating critical medical advances to the public.
Summary
Cutaneous T-cell lymphoma (CTCL), recognized as one of the most difficult cancers to diagnose early, may soon have a promising new treatment option thanks to Soligenix Inc. (NASDAQ: SNGX). This late-stage biopharmaceutical company is advancing HyBryte™ (SGX301), a novel photodynamic therapy using synthetic hypericin. Unlike traditional ultraviolet-based treatments that carry long-term safety risks, HyBryte is activated by safe visible light in the red-yellow spectrum. This innovative approach allows for targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue, addressing a critical gap in rare disease treatment. Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease, with the company seeking regulatory approvals following successful Phase 3 studies.
Soligenix's efforts, as detailed in a recent article, highlight its broader mission within its Specialized BioTherapeutics business segment. Beyond CTCL, the company is expanding synthetic hypericin into psoriasis treatments and developing first-in-class innate defense regulator technology for inflammatory diseases. Its Public Health Solutions business segment, supported by government grants, focuses on vaccine candidates for threats like ricin toxin, filoviruses (including Marburg and Ebola), and COVID-19, utilizing its proprietary ThermoVax® heat stabilization platform. For further information, visit the company's website at www.Soligenix.com, and to view the full article, visit https://ibn.fm/HmCkL.
This news was disseminated through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, which provides advanced wire-grade press release syndication and corporate communications solutions. InvestorWire ensures broad reach to investors, influencers, and the general public, with the latest updates on SNGX available in the company's newsroom at https://ibn.fm/SNGX. By leveraging a vast network and seasoned journalists, InvestorWire helps companies like Soligenix gain unparalleled recognition in a crowded market, making complex medical advancements accessible to a wide audience.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Advances Novel Light Therapy for Hard-to-Diagnose Skin Cancer
